As at 1st May 2007 the Spotlight Appeal has raised £5,608,575. This is being used to fund research into prostate cancer. The projects which have been funded to date are:
- University of Sheffield. Commenced 1 October 1999. Why do prostate cancers spread to the bones and cause new bone growth? 3 Year Funding: £120,000
- University of Bristol. Commenced 1 October 1999. How do growth factors and male hormones affect the growth and survival of prostate cancer cells? 3 Year funding: £94,000
- University of Oxford. Commenced 1 October 1999. Analysing exactly which genetic changes lead to cancer of the prostate. 3 Year funding: £121,000
- Imperial College of Science, Technology & Medicine. Commenced 1 October 2000. Investigating the mechanism of hormone therapy for prostate cancer. 3 Year funding: £142,000
- Erasmus University Rotterdam. Commenced 1 October 2000. Identifying proteins involved in prostate cancer cell suicide. 3 Year funding: £126,000
- Imperial College of Science, Technology & Medicine. Commenced 1 October 2000. Identifying the growth factors of prostate cells. 3 Year funding: £136,000
- University of Bath. Commenced 1 October 2001. Towards a polymeric prodrug system for selective delivery of cytotoxins to prostate tumours. 3 Year funding: £58,720
- University of Newcastle. Commenced 1 October 2001. Modulation of androgen receptor-mediated cellular signalling in human prostate cancer by the coactivator protein TIP60. 3 Year funding: £114,538
- University of Edinburgh. Commenced 1 April 2002. Role of CYP7B, a novel cytochrome P450 enzyme in prostate cancer progression. 3 Year funding: £139,390
- Imperial College of Science, Technology & Medicine. Commenced 1 October 2002. Functional characterisation of novel androgen receptor - interacting proteins. 3 Year funding: £75,850
-
University of Cambridge. Commenced April 2004. Dog odour discrimination and human health. 1 year funding £48,210
-
University of Leuven. Commenced April 2004. Structure-function analysis of the amino-terminal domain of the androgen receptor and its co-activators. 3 year funding: £102,204
-
University of Helsinki. Commenced April 2004. Androgen receptor-dependent transcriptional regulation in prostate cells: coregulator dynamics and the role of ubiquitin and SUMO modifications. 3 year funding: £129,108
-
University of Dundee. Commenced October 2004. PPARo as a drug target in prostate cancer. 3 year funding: £114,983
-
Newcastle University. Commenced October 2004. Regulation of HDAC1; a component of the androgen receptor transcriptosome and potential therapeutic target in prostate cancer. 3 year funding: £129,660